Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)
- Link to summary of recommendations: IDSA C difficile recommendations for adults and children
- Link to full download: IDSA/SHEA Clinical Practice Guideline for C difficile 2017 for adults and children (48 page pdf)
Summary from Infectious Disease Advisor: Updated C difficile Infection Clinical Guidance From IDSA/SHEA
The comprehensive clinical practice guideline …was endorsed by the Infectious Diseases Society of America (IDSA) and the Society for Healthcare Epidemiology of America (SHEA)…
Recommendations for treatment of CDI in adults… now favors a 10-day course of vancomycin or fidaxomicin rather than metronidazole for first-line therapy of mild/moderate CDI in adults… Fidaxomicin, also a newly recommended first-line therapy for mild/moderate CDI in adults, may reduce the risk for recurrent CDI because of its narrow spectrum compared with vancomycin.
Recommended treatment strategies for recurrent CDI, a complication that occurs in approximately 25% of patients, have also been revised…Following initial CDI treated with a 10-day course of vancomycin, either a several-week tapered and pulsed course of vancomycin or a 10-day course of fidaxomicin is recommended. For most patients, probiotics can be considered because of favorable cost and safety, although definitive efficacy data for probiotics to prevent recurrent CDI are still lacking. For multiply recurrent CDI (ie, at least 3 CDIs), correction of the patient’s underlying intestinal microbiota perturbation with fecal microbiota transplantation (FMT) should be strongly considered..
The diagnosis of CDI… Molecular tests (eg, nucleic acid amplification tests [NAATs], such as polymerase chain reaction), which do not differentiate colonization and infection, are now the most commonly used test for CDI among US hospitals. NAATs have the potential to misdiagnose patients with colonization as having CDI, particularly when used in patients with low likelihood of CDI. Thus, this guideline strongly reinforces the importance of practicing good diagnostic stewardship and limiting C difficile testing to patients with new-onset, unexplained, and clinically significant (ie, at least 3 unformed stools in a 24-hour period) diarrhea…formed stools should not be tested for C difficile, nor should patients be retested within 7 days of a previous negative C difficile test. In pediatric populations, because of the unclear role of C difficile as a cause of diarrhea in infants, children less than 12 months of age should not be tested…
If diagnostic stewardship is not an achievable goal, use of NAAT alone is likely to lead to frequent misdiagnosis of CDI among patients with C difficile colonization. In these cases, NAAT alone should be avoided and a multistep algorithm that incorporates toxin testing is recommended.
Related blog posts:
- 4 Points for C diff in Inflammatory Bowel Disease
- Overdiagnosis of C difficile with PCR Assays
- C diff Risk factors in children
- Clostridium difficile/Fecal Microbiota Transplantation Video …
- Clostridium difficile: Colonization vs. Symptomatic Infection …
- Clostridium difficile Epidemiology | gutsandgrowth
- Precise Identification of C difficile Transmission …
- Clostridium difficile in IBD | gutsandgrowth
- A C difficile two-fer | gutsandgrowth
- Keeping Up with Clostridium Difficile | gutsandgrowth
- How Common are Clostridium difficile infections …
- Predicting Severe Clostridium Difficile | gutsandgrowth
- Consensus Guidelines on FMT | gutsandgrowth